ArticleJournal of magnetic resonance imaging : JMRI2022
Evaluation of Hepatic Iron Overload Using a Contemporary 0.55 T MRI System.
Article in Journal of magnetic resonance imaging : JMRI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Evaluation of 0.55T MRI for Simultaneous R2* and Fat Fraction Quantification in the Presence of Hepatic Iron Overload and Steatosis Using Simulations and Phantoms.Magnetic resonance in medicine · 2026Article
- In-vivo liver proton density fat fraction quantification at 0.55 T: a pilot study with comparison against 3 T MRI.Magma (New York, N.Y.) · 2025Article
- Improved liver fat andMagnetic resonance in medicine · 2025Article
- Analysis of the sample size used in clinical MRI studies.PloS one · 2025Article
- Free-breathing MRI techniques for fat and RMagma (New York, N.Y.) · 2024Review
- Cardiac MRI at Low Field Strengths.Journal of magnetic resonance imaging : JMRI · 2024Review
- Tackling SNR at low-field: a review of hardware approaches for point-of-care systems.Magma (New York, N.Y.) · 2023Review
- [Low-field magnetic resonance imaging : Just less expensive or completely different?]Der Radiologe · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMRI T2* and R2* mapping have gained clinical acceptance for noninvasive assessment of iron overload. Lower field MRI may offer increased measurement dynamic range in patients with high iron concentration and may potentially increase MRI accessibility, but it is compromised by lower signal-to-noise ratio that reduces measurement precision. PURPOSE: To characterize a high-performance 0.55 T MRI system for evaluating patients with liver iron overload. STUDY TYPE: Prospective. POPULATION: Forty patients with known or suspected iron overload (sickle cell anemia [n = 5], ß-thalassemia [n = 3], and hereditary spherocytosis [n = 2]) and a liver iron phantom. FIELD STRENGTH/SEQUENCE: A breath-held multiecho gradient echo sequence at 0.55 T and 1.5 T. ASSESSMENT: Patients were imaged with T2*/R2* mapping 0.55 T and 1.5 T within 24 hours, and 16 patients returned for follow-up exams within 6-16 months, resulting in 56 paired studies. Liver T2* and R2* measurements and standard deviations were compared between 0.55 T and 1.5 T and used to validate a predictive model between field strengths. The model was then used to classify iron overload at 0.55 T. STATISTICAL TESTS: Linear regression and Bland-Altman analysis were used for comparisons, and measurement precision was assessed using the coefficient of variation. A P-value < 0.05 was considered statistically significant.
resultsR2* was significantly lower at 0.55 T in our cohort (488 ± 449 s DATA
conclusionWe demonstrated that 0.55 T provides T2* and R2* maps that can be used for the assessment of liver iron overload in patients. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.